Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Therapeutic Potential of Clusterin Inhibition in Human Cancer

Version 1 : Received: 7 February 2024 / Approved: 8 February 2024 / Online: 8 February 2024 (10:23:57 CET)

A peer-reviewed article of this Preprint also exists.

Martín-García, D.; García-Aranda, M.; Redondo, M. Therapeutic Potential of Clusterin Inhibition in Human Cancer. Cells 2024, 13, 665. Martín-García, D.; García-Aranda, M.; Redondo, M. Therapeutic Potential of Clusterin Inhibition in Human Cancer. Cells 2024, 13, 665.

Abstract

Clusterin (CLU) protein is involved in various pathophysiological processes including carcinogenesis and tumor progression. In recent years, the role of the secretory isoform has been demonstrated in tumor cells, where it inhibits apoptosis and favors the acquisition of resistance to conventional treatments used to treat cancer. To determine the possible therapeutic potential of inhibiting this protein, numerous studies have been carried out in this field. In this paper, we show the existing knowledge on the inhibition of this protein in different types of cancer and discuss the importance it could have in the development of new therapies directed against this pathology.

Keywords

clusterin; human cancer; targeted treatment; resistance; therapeutic potential.

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.